Q1 Earnings Estimate for RCUS Issued By HC Wainwright

Arcus Biosciences, Inc. (NYSE:RCUS) – HC Wainwright issued their Q1 2025 earnings estimates for shares of Arcus Biosciences in a research report issued to clients and investors on Tuesday, February 18th. HC Wainwright analyst E. Bodnar expects that the company will earn ($1.30) per share for the quarter. HC Wainwright has a “Neutral” rating and a $18.00 price objective on the stock. The consensus estimate for Arcus Biosciences’ current full-year earnings is ($3.20) per share. HC Wainwright also issued estimates for Arcus Biosciences’ Q2 2025 earnings at ($1.10) EPS, Q3 2025 earnings at ($1.15) EPS, Q4 2025 earnings at ($1.15) EPS and FY2029 earnings at ($1.80) EPS.

Other analysts have also recently issued research reports about the company. Wedbush restated an “outperform” rating and set a $36.00 price objective on shares of Arcus Biosciences in a research note on Thursday, November 7th. Bank of America dropped their price target on Arcus Biosciences from $22.00 to $17.00 and set a “neutral” rating on the stock in a research report on Wednesday. Barclays lifted their price objective on shares of Arcus Biosciences from $25.00 to $29.00 and gave the stock an “overweight” rating in a report on Friday, October 25th. Finally, Morgan Stanley dropped their target price on shares of Arcus Biosciences from $36.00 to $25.00 and set an “overweight” rating on the stock in a report on Tuesday. Two research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Arcus Biosciences has a consensus rating of “Moderate Buy” and a consensus price target of $29.50.

Arcus Biosciences Stock Performance

Shares of Arcus Biosciences stock opened at $11.09 on Thursday. The company has a debt-to-equity ratio of 0.08, a quick ratio of 5.24 and a current ratio of 5.24. Arcus Biosciences has a 1 year low of $10.65 and a 1 year high of $20.31. The firm’s 50-day simple moving average is $14.15 and its 200-day simple moving average is $15.60.

Insider Activity

In other news, CFO Robert C. Goeltz II sold 3,594 shares of Arcus Biosciences stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $15.00, for a total transaction of $53,910.00. Following the sale, the chief financial officer now owns 60,138 shares of the company’s stock, valued at approximately $902,070. The trade was a 5.64 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 12.30% of the company’s stock.

Hedge Funds Weigh In On Arcus Biosciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in RCUS. R Squared Ltd acquired a new position in Arcus Biosciences during the 4th quarter worth $26,000. Point72 Hong Kong Ltd bought a new stake in shares of Arcus Biosciences during the third quarter valued at about $47,000. Lazard Asset Management LLC lifted its holdings in Arcus Biosciences by 3,321.3% in the fourth quarter. Lazard Asset Management LLC now owns 6,261 shares of the company’s stock worth $93,000 after purchasing an additional 6,078 shares during the period. US Bancorp DE grew its position in Arcus Biosciences by 2,432.0% in the 4th quarter. US Bancorp DE now owns 6,887 shares of the company’s stock valued at $103,000 after buying an additional 6,615 shares in the last quarter. Finally, Quest Partners LLC increased its stake in Arcus Biosciences by 40,904.3% during the 3rd quarter. Quest Partners LLC now owns 9,431 shares of the company’s stock valued at $144,000 after buying an additional 9,408 shares during the period. 92.89% of the stock is owned by institutional investors.

About Arcus Biosciences

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.